# US 2021/0275660 A1 · Mannheimia haemolytica vector and mycoplasma bovis vaccine product

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275660 A1
- Document ID: US20210275660A1
- Status: Published application
- Kind: A1
- Application number: 17/190,182
- Filed: 2021-03-02
- Published: 2021-09-09
- Earliest claimed: 2020-03-03
- Assignees: The United States of America as represented by the Secretary of Agriculture
- Applicants: The United States of America, as represented by the Secretary of Agriculture
- Inventors: ROBERT E BRIGGS; FRED M TATUM
- Web page: https://patentgrep.com/patent/US20210275660A1

## CPC

- A61K 39/102: {Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus
- A61K 39/0241: {Mollicutes, e.g. Mycoplasma, Erysipelothrix}
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61P 31/04: Antibacterial agents
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/523: {expressing foreign proteins}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/543: {intranasal}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to modified Mannheimia haemolytica (M. haemolytica) lktCA gene cluster cassettes, compositions comprising such cassettes, methods of using such cassettes and compositions, and kits comprising such cassettes and compositions. Also described herein are Mycoplasma bovis (M. bovis) protective antigens, compositions comprising such antigens, methods of using such antigens and compositions, and kits comprising such antigens and compositions. Also described herein are modified M. haemolytica lktCA gene cluster cassettes engineered to express M. bovis protective antigens, compositions comprising such cassettes, methods of using such cassettes and compositions, and kits comprising such cassettes and compositions.

## Claims

### Claim 1

A modified M. haemolytica lktCA gene cluster cassette comprising a polynucleotide encoding an additional leukotoxin neutralizing epitope inserted downstream of the native leukotoxin A start codon.

### Claim 2 (depends on 1)

The modified M. haemolytica lktCA gene cluster cassette of claim 1, wherein the cassette further comprises:
a leukotoxin promotor polynucleotide,
a leukotoxin A ribosome binding site and start codon polynucleotide; and
a polynucleotide encoding at least leukotoxin A amino acids 732 to 953.

### Claim 3 (depends on 2)

The cassette of claim 2, wherein the leukotoxin promotor polynucleotide; the leukotoxin A ribosome binding site and start codon polynucleotide; the polynucleotide encoding the additional leukotoxin neutralizing epitope; and the polynucleotide encoding at least leukotoxin A amino acids 732 to 953 are from M. haemolytica strain A1 or M. haemolytica strain A6.

### Claim 4 (depends on 2)

The cassette of claim 2, wherein the leukotoxin promotor polynucleotide has the nucleotide sequence set forth in SEQ ID NO: 6; the leukotoxin A ribosome binding site and start codon polynucleotide has the nucleotide sequence set forth in SEQ ID NO: 7; the additional leukotoxin neutralizing epitope has the amino acid sequence set forth in SEQ ID NO: 9; the leukotoxin A amino acids 732 to 953 have the amino acid sequence set forth in SEQ ID NO: 10.

### Claim 5 (depends on 1)

A composition comprising the cassette of claim 1, wherein the composition is a polynucleotide, a plasmid, an expression vector, a host cell, a vaccine, or an immunogenic composition.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the composition is a replacement plasmid, an attenuated M. haemolytica strain A1 bacterium, or an attenuated M. haemolytica strain A6 bacterium.

### Claim 7 (depends on 1)

The cassette of claim 1, further comprising at least one polynucleotide encoding a heterologous antigen.

### Claim 8 (depends on 7)

The cassette of claim 7, wherein the at least one polynucleotide encoding a heterologous antigen is inserted upstream of the polynucleotide encoding the added leukotoxin neutralizing epitope.

### Claim 9 (depends on 7)

A composition comprising the cassette of claim 7, wherein the composition is a polynucleotide, a plasmid, an expression vector, a host cell, a vaccine, or an immunogenic composition.

### Claim 10

An M. bovis antigen comprising elongation factor thermo unstable protein (EF-Tu) or heat shock protein DnaK.

### Claim 11 (depends on 10)

The M. bovis antigen of claim 10, comprising EF-Tu and DnaK.

### Claim 12 (depends on 11)

The M. bovis antigen of claim 11, comprising an EF-Tu and DnaK chimera.

### Claim 13 (depends on 10)

A composition comprising the M. bovis antigen of claim 10, wherein the composition is a polynucleotide, a plasmid, an expression vector, a host cell, a vaccine, or an immunogenic composition.

### Claim 14 (depends on 7)

The cassette of claim 7, wherein the at least one polynucleotide encoding a heterologous antigen is at least one M. bovis antigen.

### Claim 15 (depends on 14)

The cassette of claim 14, wherein the at least one polynucleotide encoding an M. bovis antigen encodes EF-Tu or DnaK.

### Claim 16 (depends on 14)

The cassette of claim 14, where the at least one M. bovis antigen is a chimeric M. bovis antigen.

### Claim 17 (depends on 16)

The cassette of claim 16, wherein the chimeric M. bovis antigen comprises DnaK and EF-Tu.

### Claim 18 (depends on 14)

A composition comprising the cassette of claim 14, wherein the composition is a polynucleotide, a plasmid, an expression vector, a host cell, a vaccine, or an immunogenic composition.

### Claim 19 (depends on 5)

A method for provoking an immune response in an animal, the method comprising administering to the animal at least one effective dose of a composition of claim 5.

### Claim 20 (depends on 9)

A method for provoking an immune response in an animal, the method comprising administering to the animal at least one effective dose of a composition of claim 9.

### Claim 21 (depends on 13)

A method for provoking an immune response in an animal, the method comprising administering to the animal at least one effective dose of a composition of claim 13.

### Claim 22 (depends on 18)

A method for provoking an immune response in an animal, the method comprising administering to the animal at least one effective dose of a composition of claim 18.

### Claim 23 (depends on 1)

A kit comprising the cassette of claim 1.

### Claim 24 (depends on 7)

A kit comprising the cassette of claim 7.

### Claim 25 (depends on 10)

A kit comprising the antigen of claim 10.

### Claim 26 (depends on 14)

A kit comprising the cassette of claim 14.
